Densiron [

Small molecule

AAsociación para Evitar la Ceguera en México

Densiron [ is one of 11 small molecule programs targeting Retinal Detachment. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal DetachmentActive, not recruiting

Retinal DetachmentPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Retinal Detachment

#DrugCompanyPhaseTrials

Pred Forte

Novartis

Approved

1 2

Azilect

Teva

Approved

1 3

Minocin

Avastin

4 5

Lucentis

Roche

Phase 2

1 6

Trexall

Alnylam Pharmaceuticals

Phase 2

1 7

Dextenza

TTufts Medical Center

Approved

1 8

Epivir

GGlaxo Dba Glaxosmithkline

Phase 1

1 9

ONL1204

OONL Therapeutics

Phase 2

1 10

Denufosol Tetrasodium (INS37217)

Merck & Co.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinal Detachment1 trial

Comparison High-density Silicone Oils in Retinal Detachment

Withdrawn·AAsociación para Evitar la Ceguera en México·Phase 2/3·NCT00403702

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Densiron [. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Densiron [ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Densiron [. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Asociación para Evitar la Ceguera en México company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAsociación para Evitar la Ceguera en México

Densiron [

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinal Detachment1 trial

References

Drug Info

Quick Facts

Related News